TriangleBelantamab Mafodotin (NCT05847569)
Belantamab Mafodotin trial for Recurrent Multiple Myeloma (NCT05847569). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with myeloma progressing after at least three treatment lines covering a proteasome inhibitor, an immunomodulator, and an anti-CD38 antibody. Previous belantamab is excluded; other BCMA treatments are allowed.
The idea: belantamab mafodotin delivers a cell-division-blocking payload to BCMA-bearing cells. Randomization compares infusions every six weeks with two infusions three weeks apart, then six-week intervals. Researchers test approaches for eye toxicity and cancer response. Blood, marrow, and imaging assessments follow.
This phase 2 study plans 62 patients. Ricardo Parrondo leads at Mayo Clinic, Jacksonville, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.